GlaxoSmithKline Royalties Come Under Scrutiny
Massachusetts-based biopharmaceutical company Avant Immunotherapeutics Inc. said on Wednesday that GlaxoSmithKline has been paying the lower of two royalty rates on its sales for a rotavirus vaccine in Australia and several...To view the full article, register now.
Already a subscriber? Click here to view full article